Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label study of Levemir and NovoRapid in type 1 diabetes
2006-002478-23Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of insulin detemir and insulin aspart in diabetes mellitus type 1 (T1D), sponsored by Novo Nordisk. Primary endpoints: Development of insulin detemir-insulin aspart cross-reacting antibodies, Development of insulin detemir specific antibodies and 1 more. Started Aug 2007; status: completed.
02
Drugs
insulin detemirinsulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2006-002478-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002478-23.